RU2158129C2 - Method for treating the cases of lupus erythematosus - Google Patents

Abstract

FIELD: medicine. SUBSTANCE: method involves intramuscularly administering autoblood once a day at a dose of 5 cm³ saturated with 15 cm³ of ozone and oxygen mixture with ozone concentration of 30 mcg/ml in addition to aminoquinoline preparations or presocyl with nicotinic acid in the same syringe twice a week. The course is to 10 injections long. An additional intramuscular injections course is carried out once a day with 10 cm³ of ozone and oxygen mixture having ozone concentration of 30 mcg/ml. The injections are done three times a week with total amount of up to 10 injections. EFFECT: enhanced effectiveness of treatment; avoided adverse side effects; low cost. 1 tbl

Description

 The invention relates to medicine, namely to dermatology, can be used to treat patients with integumentary forms of lupus erythematosus.

 Lupus erythematosus is a systemic disease with an unknown etiology and complex pathogenesis, expressed photosensitivity. A triad of clinical signs is characteristic: erythema, follicular hyperkeratosis, skin atrophy. Rashes are localized mainly in areas of the skin that are unprotected from the sun.

 In the pathogenesis of lupus erythematosus, the leading role belongs to immune, metabolic, neuroendocrine and exogenous factors. Various B-cell activators, including infections, can be provocative; immunization with modified lymphocytic antigens, nuclear antigens due to viremia; altered exogenous (insolation, ultraviolet irradiation) or endogenous (drugs) effects.

 The most convincing immunological concept of lupus erythematosus, which is considered the standard of non-organ-specific autoimmune diseases.

 In the treatment of lupus erythematosus, the use of bidirectional therapy is advisable: on the one hand, which reduces the pathogenic activity of the immunocomplex reaction; on the other hand, it stimulates the oppressed nonspecific resistance of the body. The severity and variety of immunological disorders in this disease makes us search for new immunomodulators that increase the effectiveness of treatment.

 The closest in essence and chosen by the authors as a prototype is a method of treating lysozyme in the complex therapy of patients with lupus erythematosus, including aminoquinoline derivatives (delagil), presocyl and nicotinic acid preparations (1). Lysozyme is an enzyme of protein nature, which is one of the constitutive lysosomal acid hydrolases contained in various tissues and body fluids. It is a modulator of intercellular interactions in the focus of inflammation, causes activation of the surface structures of macrophages, increases metabolism. The action of delagil is associated with an inhibitory effect on DNA synthesis. It also has a mild anti-inflammatory and immunosuppressive effect.

 The treatment was carried out either with small doses of lysozyme (30 mg sublingually three times a day) or daily by intramuscular injection of 300 mg of lysozyme for 10 days, after which delagil was administered 0.25 g twice a day for 5-day cycles against nicotinic acid preparations. Some patients with disseminated lupus erythematosus received presocil in a descending manner.

 In two patients with dioxide lupus erythematosus (3.5%), the use of lysozyme caused toxidermia. The end result of the complex treatment, including delagil or presocyl and nicotinic acid, was the disappearance of clinical manifestations in 54.4% of patients, a significant improvement in 36.8% and an improvement in 8.8%.

 The known method has disadvantages: more limited indications, since its effectiveness increases with lower body resistance.

 The task of the invention is to increase the effectiveness of treatment and reduce side effects.

The problem is solved by a method of treating lupus erythematosus, including the administration of aminoquinoline preparations or presocyl, in which, in accordance with the proposed solution, 5 cm ^{3 of} autologous blood saturated with 15 cm ^{3 of an} ozone-oxygen mixture with an ozone concentration of 30 μg / ml are additionally intramuscularly administered one syringe twice a week up to 10 injections and intramuscularly injected once a day 10 cm ^{3 of an} ozone-oxygen mixture with an ozone concentration of 30 μg / ml three times a week up to 10 injections.

The method is as follows: a patient with a diagnosis of lupus erythematosus is administered twice a week with a small autohemotherapy (15 cm ^{3 of an} ozone-oxygen mixture with an ozone concentration of 30 μg / ml is mixed with 5 cm ^{3 of} autologous blood and administered intramuscularly up to 10 injections) and three times a week carry out intramuscular injection of 10 cm ³ ozone-oxygen mixture with an ozone concentration of 30 μg / ml up to 10 injections. This allows you to increase the effectiveness of the treatment due to the immunomodulating effect of the ozone-oxygen mixture.

 To prove the effectiveness of the proposed method, 32 patients with integumentary forms of lupus erythematosus were monitored (22 patients suffered from a discoid form of the disease, 10 - disseminated). All patients showed good tolerance to ozone therapy. Ozone monotherapy was carried out for 10-14 days, after which the traditional complex treatment was prescribed, including delagil, nicotinic acid preparations, and presocil for individual patients with disseminated lupus erythematosus.

 The table presents comparative data on the proposed method of the invention and the prototype.

 After monozone therapy, in two patients the clinical manifestations of the disease regressed completely, in 11 there was a significant improvement, in 13 - an improvement. In 6 patients, significant changes in clinical manifestations did not occur.

 After complex treatment, regression of clinical manifestations was observed in 17 people, a significant improvement in 14, an improvement in 1 patient.

 Examples of specific performance.

Example 1
Patient A., 24 years old, East. bol. 726, was admitted to the NIKVI clinic on 10.04.96 with complaints of rashes on the face, ears, red border of the lips, accompanied by burning. The duration of the disease is 4 years. The pathological process was represented by atrophy, against which there was a bright edematous erythema with a layering of gray-white, tight-fitting scales. Diagnosis: discoid lupus erythematosus.

The following treatment was carried out: small autohemo-ozonotherapy N 10, intramuscular injections of 10 cm ^{3 of an} ozone-oxygen mixture with an ozone concentration of 30 μg / ml N 10, delagil 0.25 g 2 times a day, 5-day cycles with three-day intervals - 5 cycles, 5% the solution delagil 5 ml intramuscularly N 6, 1% solution of nicotinic acid 2 ml intramuscularly N 37, externally - Sinaflan ointment. The regression of clinical manifestations began after 7 days of therapy; at the end of monozone therapy, clinical manifestations were absent. The patient was discharged 05/21/96, with the disappearance of the clinical picture of the disease: rashes completely regressed, leaving severe hyperpigmentation.

 Example 2

 Patient T., 22 years old, East. bol. 350, was admitted to the NIKVI clinic on 02.21.96 with complaints of multiple rashes on the face, neck, chest, back, back surfaces of the hands, weakness and arthralgia. Ill 1 year ago. The pathological process was represented by small foci with bright erythema, peeling and atrophy of the skin. Diagnosis: dissemination of lupus erythematosus.

The following treatment was carried out: small autohemo-ozonotherapy N 10, intramuscular injections of 10 cm ^{3 of an} ozone-oxygen mixture with an ozone concentration of 30 μg / ml N 10, presocyl according to the scheme of 6 tablets with a dose reduction of 1 tablet after 5 days, then 1% nicotinic acid solution 2 ml intramuscularly N 30 and a 5% solution delagil 5 ml intramuscularly N 10, externally - Flucinar ointment. The regression of clinical manifestations was noted after 10 days of therapy. The patient was discharged 04/04/96, with the disappearance of the clinical picture of the disease.

Thus, the proposed method has the following advantages, compared with the prototype:
- increases the effectiveness of treatment,
- characterized by the absence of side effects,
- It is economically feasible through the use of low-cost equipment.

Claims (1)

A method of treating patients with lupus erythematosus by administering aminoquinoline preparations or presocyl and nicotinic acid, characterized in that they additionally intramuscularly administer 5 cm ^{3 of} autologous blood saturated with 15 cm ^{3 of} ozone-oxygen mixture with an ozone concentration of 30 μg / ml in one syringe two once a week up to 10 injections and intramuscularly injected once a day 10 cm ^{3 of an} ozone-oxygen mixture with an ozone concentration of 30 μg / ml three times a week up to 10 injections.

Images